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Conclusions 
 Imatinib exposure at treatment 
initiation (CL~initial dose/AUC) 
 CML phase and time on treatment  
 Male patients:     increased risk 
of suboptimal response 
 Prospective study needed 
Observational study: Pharmacological 
Monitoring Project of EUTOS (European 
Treatment & Outcome Study, 2006-2010)3. 
PK variables: log-normalized Cmin (log-Cmin) 
or clearance (CL), adjusted to initial dose 
Others: Time on imatinib treatment (stratified 
at 3 years), sex, CML phase, age, potentially 
interacting comedication, TDM frequency. 
Sequential PK/PD analysis (NONMEM 7):  
1. Population PK analysis (FOCE-interaction) 
  individual Bayesian estimates of 
exposure (PK) 
2. Mixed-effect logistic regression (ITS) 
 PD (optimal MR) ~ PK + covariates + η 
  
  
Imatinib is a first-line drug for CML with 
considerable pharmacokinetic variability. 
Therapeutic drug monitoring (TDM) has 
been increasingly proposed, as trough 
concentrations (Cmin) have been correlated 
with improved response in prospective 
trials.1,2 
Probability of achieving optimal molecular response to imatinib treatment  
in chronic myeloid leukemia (CML) patients 
 
 Univariate analysis: CL, log-Cmin, time 
on treatment, TDM frequency, gender (all 
p<0.01) & CML phase (p=0.02) were 
significant predictors of the PD outcome. 
 Stepwise multivariate regression: all but 
log-Cmin (p=0.34) remained significant. 
Methods 
Results 
PK/PD analysis 
Small impact confirmed on the probability of 
molecular response in observational setting 
Expectedly correlated to outcome 
Compliance- or concentration related (18.5% 
higher CL) ? 
 
Population PK analysis Mixed-effect logistic regression 
Introduction 
Objective 
Background Study scope 
Table 1: Data -  patient and sample characteristics 
Patients [n] 1299  
Gender [n] male : female 728: 571 
Observations [n] 2230 
Estimated Cmin (adj) [ng/ml] median (range) 797 (231-4602) 
Estimated CL [L/h] median (range) 14.4 (5-28) 
Age [years]  median (range) 56 (18-92) 
Daily dose [mg]  mean (sd) 462 (124) 
Months on imatinib  median (range) 45 (18-143) 
Comedication  [n] Present : unknown 1682 : 548 
Table 3: Summary  
of PK/PD model 
Estimate  
(SE) 
BL π  
[95% CI] 
« Baseline patient »: 
average CL of 16 L/h 
0.105 
(0.125) 
52.6% 
[46.5-58.7%] 
Time on imatinib  
> 3 years 
+1.08 (0.130) 76.6% [71.7-80.8%] 
TDM only once  -0.65 (0.128) 36.8% [31.2-42.8] 
Male sex -0.48 (0.127) 40.9% [35.0-47.0%] 
Accelerated phase -1.29 (0.534) 23.4% [9.7-46.5%] 
Individual CL, increase  
by 1 L/h from 16 L/h  
8.0 L/h : 22.2 L/h  
(percentile 5 : 95) 
-0.037 
(0.014) 
 
 
59.9% : 46.9% 
η (BSV variability) 1.34 (0.6) +/- η: 22.5-80.9% 
+/- 1.96η: 7.5-93.9% 
Covariates considered 
Pharmacokinetic/Pharmacodynamic (PK/PD) relationships observed under field-conditions 
 
to confirm clinical importance of identified covariates 
to exclude biases possibly affecting this observational survey 
Fig-1: Individual Bayesian estimates of exposure derived from the 
population PK analysis. Left: Individual Cmin estimates, adjusted to daily 
standard dose of 400 mg (Cmin(adj)), observations >3000 ng/ml not shown (n= 2). 
Right: Individual clearance estimates (CL/F) together with corresponding 
estimates of dose-adjusted area under the concentration-time curve (AUC0-24). 
Table 2: Summary of  
population PK model 
Point  
estimate 
RSE
% 
Structural parameters (1-compartment, 0-order absorption) 
Duration of absorption (D1) 
Clearance (CL/F) 
Volume of distribution (V/F) 
3.2 h 
17.3 L/h (male)  
429 L 
10.2% 
9.6% 
10.2% 
Between-subject variability 
CV%CL/F 
CV%V/F 
CorrelationCL/F-V/F 
CV%σ1 
37.7% 
51.1% 
0.75 
35.4% 
12.1% 
39.5% 
27.6% 
41.8% 
Intra-individual (residual) variability 
Proportional part, σ1 (CV%) 
Additive part, σ2 
29.1% 
84.6 ng/ml 
4.5% 
22.8% 
Covariate-Model:  TVCL = CL (1+θ1) (1+θ2 (age-40)) 
female on CL/F: θ1  
If age < 40 years: θ2 on CL/F 
If age > 40 years: θ2 on CL/F 
-0.152 (-15.2%) 
0.00403 
-0.00568 
12.3% 
73.2% 
12.9% 
RSE% relative standard error. CV: coefficient of variation. 
Derived exposure estimates 
Contact 
Verena Gotta, Division de Pharmacologie clinique, Centre Hospitalier Universitaire Vaudois (CHUV), 1011 Lausanne Verena.Gotta@chuv.ch  
PK/PD relationships 
Fig-3: Impact of other patient-related factors on optimal molecular 
response (MR) and comparison with impact of CL/F.  Estimated odds ratios 
with 95% confidence intervals  (PK/PD model) 
To evaluate the impact of imatinib 
exposure on optimal molecular response 
(MR) rates in a large European cohort of 
patients followed by centralized TDM. 
SE: standard error. BL π: baseline probability, corresponding to an odds ratio 
of 1. CI: confidence interval. BSV: between-subject variability. 
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Cmin(adj): trough concentration adjusted to standard (initial) dose of 400mg daily. 
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Fig-2: Impact of exposure 
on optimal molecular 
response (MR).  Probability 
over CL/F, illustrated for a 
“baseline patient” with 
changing CL/F. 
